Genus’ (GNS) “Hold” Rating Reaffirmed at Liberum Capital
GNS has been the subject of a number of other reports. N+1 Singer raised shares of Genus to a buy rating and lifted their price target for the company from GBX 1,844 ($25.48) to GBX 2,485 ($34.33) in a research report on Monday, October 30th. Kepler Capital Markets initiated coverage on shares of Genus in a research report on Tuesday, November 7th. They set a hold rating and a GBX 2,353 ($32.51) price target for the company. Finally, Peel Hunt reissued a buy rating and set a GBX 2,600 ($35.92) price target on shares of Genus in a research report on Wednesday, November 15th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of GBX 2,270.60 ($31.37).
Genus (GNS) opened at GBX 2,316 ($32.00) on Monday. Genus has a 12-month low of GBX 1,652 ($22.82) and a 12-month high of GBX 2,597 ($35.88). The stock has a market cap of $1,430.00 and a PE ratio of 4,369.81.
COPYRIGHT VIOLATION WARNING: “Genus’ (GNS) “Hold” Rating Reaffirmed at Liberum Capital” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://theolympiareport.com/2018/02/15/genus-gns-hold-rating-reaffirmed-at-liberum-capital.html.
Genus plc is an animal genetics company, which provides farmers with genetics that enable them to produce animal protein, in the form of meat and milk. The Company’s segments include Genus PIC, Genus ABS, Genus Asia, and Research and Development. The Genus PIC segment is engaged in porcine sales business, excluding Asia, and serves porcine customers in North America, Latin America and Europe.
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.